Redeye Interview – Magnus Corfitzen presents an update on Orviglance NDA and Financing

2025-09-29

Magnus Corfitzen, CEO of Ascelia Pharma AB, discusses the NDA submission to the FDA for Orviglance and the recent SEK 30 million share issue